A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Clinical trial NCT05950165 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05950165
- Sponsor
- Cho Pharma Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-15
- Primary completion
- 2026-12-23
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.